GCLC-mediated suppression of ferroptosis contributes to lenvatinib resistance in HCC organoids and xenografts. Functional genomic screening revealed that hepatocellular carcinoma (HCC) survival ...
An ongoing open-label extension study suggests that the therapy's benefits may extend through at least 52 weeks. Deupirfenidone (LYT-100), a next-generation antifibrotic therapy, demonstrated a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback